Dominari Inc. (DOMH)
7.44
0.70 (10.39%)
At close: Mar 05, 2025, 3:11 PM
10.39% (1D)
| Bid | 7.28 |
| Market Cap | 107.06M |
| Revenue (ttm) | 28.64M |
| Net Income (ttm) | -51.61M |
| EPS (ttm) | -3.96 |
| PE Ratio (ttm) | -1.88 |
| Forward PE | -1.33 |
| Analyst | n/a |
| Ask | 7.45 |
| Volume | 481,189 |
| Avg. Volume (20D) | 1,688,301 |
| Open | 6.78 |
| Previous Close | 6.74 |
| Day's Range | 5.95 - 7.60 |
| 52-Week Range | 0.83 - 13.58 |
| Beta | 1.12 |
About DOMH
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also d...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 18, 1980
Employees 26
Stock Exchange NASDAQ
Ticker Symbol DOMH
Website https://www.aikidopharma.com
1 week ago
-7.56%
Dominari Holdings shares are trading higher after ...
Unlock content with
Pro Subscription
1 week ago
-17.26%
Shares of companies in the broader financial sector are trading lower amid overall market weakness on US consumer and economic concerns.
2 weeks ago · accessnewswire.com
Dominari Announces Strategic Entry into U.S. AI Data Center MarketSpecial Cash Dividend Determined to be $0.32 per Share. NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Dominari Holdings Inc. (Nasdaq:DOMH) (the "Company" or "Dominari") today announced the...
